Cannabis Substitution Reduces Opioid Use in Patients With Chronic Pain

In a large nationwide survey study (N=1321), my colleagues and I found that individuals using cannabis for chronic pain management reported reductions in the use of opioids and other pain medications.1 In our retrospective study, 53%
(n=691) of participants substituted cannabis for opioids and 22% (n=287) for benzodiazepines, with more than 65% of substitutors reporting discontinued use of these medications due to better symptom management and fewer side effects.

These results corroborate our 2016 pilot study (N=185), which showed a 64% decrease in opioid consumption among patients using medical cannabis for chronic pain management.2 The rationale and effect size are consistent with studies conducted in Canada that similarly gauge substituting cannabis for other medications.3

Our study population was 59% female with a mean age of 49.8 years (SD±13.8), reflecting the population demographic in which chronic pain is common—older adults and women.4

Cannabis as an Opioid Alternative
The poor performance of many pain medications, including high numbers needed to treat (NNT) and challenging side-effect profiles, have many looking for alternatives that have greater analgesic efficacy.5,6 Additionally, the ongoing opioid crisis has
made it more difficult to obtain opioid prescriptions, and the increasing social acceptance of cannabis as a safe, alternative medication may be driving people toward opioid alternatives.7,8 Although our data are observational and retrospective, the pattern emerging from these and numerous similar studies makes it clear that some individuals derive benefit from cannabis-based medicines—enough so that they discontinue traditional pain medications.

Strategies for Effectively Substituting Cannabis for Opioids
Despite this pattern, however, we must proceed cautiously, as other studies report that cannabis use is associated with worse clinical pain symptoms and prescription
medication misuse.9,10 Although some may frame these incongruent findings as conflicting, we believe that they instead suggest that there are subsets of individuals for whom cannabis is unhelpful (or even harmful), and others for whom substitution is possible and clinically useful. Thus, the pressing questions moving forward are how and in which clinical populations this substitution can be done most effectively.

Although we did not examine whether participants modified their medication regimen under the guidance of medical professionals, some recent studies provide
intriguing hints of how clinicians might help patients effectively substitute cannabis
for opioids. For example, Sagy et al. reported that patients with fibromyalgia (N=367)
were guided by a certified nurse through a slow, methodical titration regimen of delta9-tetrahydrocannabinol (THC) oil and/or cannabis flower. After 6 months, participants reported significant improvements in pain and quality of life, as well as decreased opioid and benzodiazepine use.11

Similar effects were found in a study examining patients with chronic pain (N=600; unspecified conditions) who were undergoing an opioid taper. Participants were given access to sublingual, oral, and/or vaporized cannabis products with appropriate
education on dose titration, as well as online psychological support tools. Eighty-one percent of participants discontinued or reduced their opioid dose and all but one participant reported satisfaction with sleep, pain control, and quality of life.12

Additionally, 2 recent clinical trials shed light on important mechanisms by which cannabidiol (CBD) and THC may alleviate opioid withdrawal or reduce opioid consumption. In the first study, Hurd et al. showed that CBD reduced cue-related anxiety and craving among individuals in recovery from heroin use disorder, suggesting that CBD may assist in quelling symptoms related to opioid addiction or dependence (and perhaps other substance use disorders as well).13

In the second study, Cooper et al. found that smoked THC dominant cannabis combined with subthreshold doses of oxycodone provided similar pain relief as a higher dose of oxycodone, providing plausibility that individuals could reduce opioid consumption by adding cannabis into their treatment regimen.14

Taken together with the observational studies mentioned above, these findings highlight several important factors for substituting effectively: flexible dosing regimens (both in terms of cannabinoids and administration routes), educational supports for both cannabis titration and pain-related symptoms, and psychological services.

Tips for Providing Clinician Oversight in Cannabis Treatment
Although federal restrictions present challenging barriers to conducting rigorous cannabis studies (especially randomized clinical trials), cannabis is becoming increasingly available. States have continued to pass both medical and adult-use cannabis legislation, and hemp-derived CBD products are available in nearly
all states.15

In this context, patients can and will use cannabis for symptom management. Despite the lack of strong clinical trials that give explicit dosing guidance, clinicians can still provide sound clinical oversight by:

• Developing treatment plans that take into account patient expectations/goals (eg, substitution) and that include symptom tracking;

• Employing harm-reduction strategies (eg, avoid smoking, “start low, go slow”); and

• Ensuring patients know the limits of both the evidence and the regulatory system in place—especially for CBD products, which often are inaccurately labeled and do not
undergo stringent safety testing.15

In so doing, clinicians can embody the practice of evidence based medicine by synergizing the best available scientific evidence with compassionate clinical expertise that accounts for the preferences and rights of patients with whom they are making
clinical decisions.16 This is not yielding to a health fad, but taking a step toward demystifying cannabis so it can be judiciously used as medicine.

References

  1. Boehnke KF, Scott JR, Litinas E, Sisley S, Williams DA, Clauw DJ.
    Pills to pot: observational analyses of cannabis substitution among
    medical cannabis users with chronic pain. J Pain. 2019;20(7):830-841.
  2. Boehnke KF, Litinas E, Clauw DJ. Medical cannabis use is associated
    with decreased opiate medication use in a retrospective cross-sectional
    survey of patients with chronic pain. J Pain. 2016;17(6):739-744.
  3. Lucas P, Baron EP, Jikomes N. Medical cannabis patterns of use and
    substitution for opioids and other pharmaceutical drugs, alcohol,
    tobacco, and illicit substances; results from a cross-sectional survey of
    authorized patients. Harm Reduct J. 2019;16(1):9.
  4. Dahlhamer J, Lucas J, Zelaya C, et al. Prevalence of chronic pain and
    high-impact chronic pain among adults – United States, 2016. MMWR
    Morb Mortal Wkly Rep. 2018;67(36):1001-1006.
  5. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for
    neuropathic pain in adults: a systematic review and meta-analysis.
    Lancet Neurol. 2015;14(2):162-173.
  6. Clauw DJ. Pain management: fibromyalgia drugs are ‘as good as it gets’
    in chronic pain. Nat Rev Rheumatol. 2010;6(8):439-440.
  7. Dowell D, Haegerich T, Chou R. No shortcuts to safer opioid
    prescribing. N Engl J Med. 2019;380(24):2285-2287.
  8. Keyhani S, Steigerwald S, Ishida J, et al. Risks and benefits of
    marijuana use: a national survey of US adults. Ann of Intern
    Med. 2018;169(5):282-290.
  9. Campbell G, Hall WD, Peacock A, et al. Effect of cannabis use in
    people with chronic non-cancer pain prescribed opioids: findings from
    a 4-year prospective cohort study. Lancet Public Health.
    2018;3(7):e341-e350.
  10. Caputi TL, Humphreys K. Medical Marijuana users are more likely to
    use prescription drugs medically and nonmedically. J Addict Med.
    2018;12(4):295-299.
  11. Sagy I, Bar-Lev Schleider L, Abu-Shakra M, Novack V. Safety and
    efficacy of medical cannabis in fibromyalgia. J Clin Med. 2019;8(6).
  12. Rod K. A Pilot study of a medical cannabis – opioid reduction
    program. Am J Psychiatr Neurosci. 2019;7(3):74-77.
  13. Hurd YL, Spriggs S, Alishayev J, et al. Cannabidiol for the reduction of
    cue-induced craving and anxiety in drug-abstinent individuals with
    heroin use disorder: a double-blind randomized placebo-controlled
    trial. Am J Psychiatry. 2019;176(11):911-922.
  14. Cooper ZD, Bedi G, Ramesh D, et al. Impact of co-administration of
    oxycodone and smoked cannabis on analgesia and abuse liability.
    Neuropsychopharmacology. 2018;43(10):2046-2055.
  15. VanDolah HJ, Bauer BA, Mauck KF. Clinicians’ guide to cannabidiol
    and hemp oils. Mayo Clin Proc. 2019;94(9):1840-1851.
  16. Sackett DL, Rosenberg WMC, Gray JAM, Haynes RB, Richardson
    WS. Evidence based medicine: what it is and what it isn’t — it’s about
    integrating individual clinical expertise and the best external evidence.
    Br Med J. 1996;312(7023):71-72.